The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'

G Atalay, L Dirix, L Biganzoli, L Beex, M Nooij, D Cameron, C Lohrisch, T Cufer, J P Lobelle, M R Mattiaci, M Piccart, R Paridaens

Research output: Contribution to journalArticlepeer-review

Abstract

The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients.
Original languageEnglish
Pages (from-to)211-7
Number of pages7
JournalAnnals of Oncology
Volume15
Issue number2
Publication statusPublished - Feb 2004

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Androstadienes
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Arteriosclerosis
  • Breast Neoplasms
  • Cholesterol
  • Enzyme Inhibitors
  • Female
  • Humans
  • Lipids
  • Middle Aged
  • Neoplasm Metastasis
  • Postmenopause
  • Risk Factors
  • Tamoxifen

Fingerprint

Dive into the research topics of 'The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients''. Together they form a unique fingerprint.

Cite this